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Abstract 
Background/Objective: In order to monitor tissue oxygenation in patients with acute neurological disorders, probes 
for measurement of brain tissue oxygen tension  (ptO2) are often placed non-specifically in a right frontal lobe loca-
tion. To improve the value of  ptO2 monitoring, placement of the probe into a specific area of interest is desirable. We 
present a technique using CT-guidance to place the  ptO2 probe in a particular area of interest based on the individual 
patient’s pathology.
Methods: In this retrospective cohort study, we analyzed imaging and clinical data from all patients who underwent 
CT-guided  ptO2 probe placement at our institution between October 2017 and April 2019. Primary endpoint was 
successful placement of the probe in a particular area of interest rated by two independent reviewers. Secondary out-
comes were complications from probe insertion, clinical consequences from  ptO2 measurements, clinical outcome 
according to the modified Rankin Scale (mRS) as well as development of ischemia on follow-up imaging. A historical 
control group was selected from patients who underwent conventional  ptO2 probe placement between January 
2010 and October 2017.
Results: Eleven patients had 16 CT-guided probes inserted. In 15 (93.75%) probes, both raters agreed on the correct 
placement in the area of interest. Each probe triggered on average 0.48 diagnostic or therapeutic adjustments per 
day. Only one infarction within the vascular territory of a probe was found on follow-up imaging. Eight out of eleven 
patients (72.73%) reached a good outcome (mRS ≤ 3). In comparison, conventionally placed probes triggered less 
diagnostic and therapeutic adjustment per day (p = 0.007). Outcome was worse in the control group (p = 0.024).
Conclusion: CT-guided probe insertion is a reliable and easy technique to place a  ptO2 probe in a particular area of 
interest in patients with potentially reduced cerebral oxygen supply. By adjusting treatment aggressively according to 
this individualized monitoring data, clinical outcome may improve.
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Introduction
Cerebral oxygen supply is a critical parameter in the 
treatment of patients with acute cerebral disorders 
such as traumatic brain injury (TBI) and subarachnoid 
hemorrhage (SAH). Cerebral tissue hypoxia poses cel-
lular metabolism and viability at risk and can cause 
secondary brain injury in these patients. Invasive 
measurement of brain tissue oxygen tension  (ptO2) 
allows continuous monitoring of cerebral oxygena-
tion and early detection of evolving ischemia [1–5]. 
 ptO2 measurements are taken by introducing a small, 
oxygen-sensitive catheter into the brain tissue through 
a burr hole. A drop of  ptO2 below 10  mmHg is asso-
ciated with cerebral ischemia and cell death [6, 7]. 
Accordingly, lower  ptO2 values are associated with 
unfavorable outcome and higher mortality in clinical 
studies of patients with TBI [8, 9]. Importantly, tis-
sue hypoxia can occur even in the absence of macro-
vascular ischemia or intracranial hypertension; thus, 
 ptO2 measurements provide additional prognostic 
information [10–12]. Several retrospective studies as 
well as a recent, prospective randomized phase II trial 
suggest a clinical benefit with improved outcome and 
lower mortality when guiding therapy according to 
 ptO2 and intracranial pressure (ICP) compared to ICP 
alone in patients suffering from TBI [13–19]. Cur-
rently, the randomized controlled phase III BONANZA 
trial (Australian New Zealand Clinical Trials Registry 
ACTRN12619001328167) as well as the BOOST-3 trial 
(clinicaltrials.gov NCT03754114) is recruiting patients 
with severe TBI in order to provide further evidence. 
In aneurysmal SAH, impaired  ptO2 values were shown 
to correlate significantly with angiographic intracranial 
arterial caliber reduction, cerebral infarction, and sur-
vival [12, 20–22]. Furthermore,  ptO2 directed therapy 
was shown to be associated with improved outcome 
after SAH [23]. However, the association of lower  ptO2 
values and outcome was only weak in clinical studies of 
patients suffering from SAH and results have been con-
flicting [12, 24, 25]. Importantly, the  ptO2 measurement 
is focal and covers only a very limited brain volume in 
the range of a few cubic millimeters [2, 4]. Thus, detec-
tion of critical cerebral perfusion due to vasospasms in 
SAH patients depends on the positioning of the  ptO2 
probe, which might explain the conflicting results [25, 
26].
For routine clinical use, a  ptO2 probe is often inserted 
through a standard frontal burr hole and placed in the 
white matter of the right frontal lobe. Many institutions 
use triple or quadruple lumen bolts for multimodal 
intracranial monitoring consisting of ICP,  ptO2, cer-
ebral blood flow, microdialysis, brain temperature, and/
or intracranial electroencephalography [27]. While this 
approach minimizes trauma by limiting the number of 
burr holes, it does not take into account the individual 
patient’s pathology. The brain metabolic profile largely 
depends on the probe location with respect to a brain 
lesion [28, 29]. Hence, selective placement of the probe 
into a particular area of interest is crucial to provide 
clinically useful information [1]. Hence, non-specific 
placement of the probe will lower the diagnostic value 
of the measurement and ultimately jeopardize the out-
come of the patient.
Here, we describe a new, fast, and easy to apply tech-
nique using CT-guidance to place the  ptO2 probe in a 
particular area of interest, which is selected for each 
patient individually. The aim of the present study was 
to assess the accuracy, applicability, and clinical value of 
CT-guided  ptO2 probe placement. We hypothesized that 
by CT-guidance, we are able to place the  ptO2 probes in 
a particular area of interest with a high rate of success, 
which would translate into improved monitoring and 
care of patients with acute neurological disorders with 
the potential to improve outcome.
Methods
Standard Protocol Approvals, Registrations, and Patient 
Consents
This is a retrospective cohort study of patients treated at 
the University Hospital of Bern. We obtained approval 
from the local ethics committee (Kantonale Ethikkom-
mission Bern, Switzerland) for this study (Project ID 
2019-00921), which, because of the retrospective analysis 
of routine data, waived the need for individual informed 
consent for the study and allowed the further use of 
health care data if the patient or next-of-kin had followed 
the general consent procedure.
Patient Population
We included all patients, who had a  ptO2 probe inserted 
between January 2010 and April 2019. Inclusion criteria 
for the study population were insertion of a  ptO2 probe 
by CT-guidance, which was routinely performed between 
October 2017 and April 2019, and age ≥ 18  years. For 
the historical control group, inclusion criteria were con-
ventional, free-hand insertion of a  ptO2 probe, which 
was routine before October 2017, and age ≥ 18  years. 
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Inclusion was irrespective of the underlying pathology, 
but most patients suffered either from TBI or SAH.
Intervention
The indications for placement of a  ptO2 probe were:
1. Risk of evolving ischemia because of cerebral vasos-
pasms and inability to monitor clinically in patients 
suffering from aneurysmal SAH.
2. Critical ICP elevation despite maximal conservative 
therapy and potential need for intermittent moderate 
hyperventilation in patients suffering from traumatic 
brain injury or intracerebral hemorrhage.
We determined for each patient individually an area 
of interest for  ptO2 measurements based on clinical 
grounds as well as radiological signs of hypoperfusion 
on CT-perfusion imaging, vasospasm of the basal cere-
bral arteries on angiography, or perifocal edema of mass 
occupying lesions. Generally, we aimed at placing the 
 ptO2 probe in an area at risk for hypoxic brain injury. In 
patients with vasospasms in the territories of the ante-
rior cerebral artery (ACA) and the middle cerebral artery 
(MCA), we aimed for the watershed zone between these 
two supply areas. Contrary, in patients with vasospasms 
in only one of these vessels, we aimed for the specific 
supply area. If the patient had a preexisting intraparen-
chymal hematoma, contusion, or infarction, that area 
was avoided. In patients with traumatic brain injury, we 
aimed for the frontal lobe on the side, which was more 
affected by intracranial injuries or for the right frontal 
lobe, if both sides were equally affected. A target area was 
chosen at a safe distance from hemorrhagic contusions 
and preexisting external ventricular drains. Anatomically, 
the probes were aimed for the watershed zone between 
the ACA and MCA supply area or in the anterior MCA 
territory if access to the watershed zone was restricted by 
a preexisting external ventricular drain.
The technique of CT-guided  ptO2 probe insertion was 
modified and derived from our recent description of 
CT-guided insertion of external ventricular drains [30]. 
The exclusive use of single lumen bolts allowed inser-
tion of  ptO2 probes irrespective of the location other 
neuro-monitoring devices. Because the commercially 
available bolt-kit  ptO2 probe (LICOX, Integra LifeS-
ciences, Plainsboro, NJ) has to be inserted at a fixed 
depth of 30  mm from the inner table or 35  mm from 
the outer table of the skull bone into the brain, we pro-
jected a sphere with a radius of 35 mm with the area of 
interest in the center of the sphere onto the patient’s CT 
scan. We then selected a point on the intersection line 
with the outer table of the skull, which was suitable for 
burr hole placement and probe insertion. The distance 
to well-defined craniometrics landmarks (midline, 
nasion, bregma, coronal suture, or an existing external 
ventricular drain) was measured on the CT scan. We 
transferred these measurements onto the patient’s skull 
and placed the burr hole accordingly. Burr hole place-
ment and bolt insertion were performed in a standard 
manner in the CT or angiography suite. We use pov-
idone-iodine (Betadine; Mundipharma, Basel, Swit-
zerland) or chlorhexidine (chlorhexidine 2% alcoholic 
uncolored, B. Braun Medical, Melsungen, Germany) 
and surgical drapes for skin preparation. The surgeon 
incised the skin over approximately 5 mm at the site of 
the planned burr hole. The burr hole was drilled with a 
manually operated twist drill. After the dura was perfo-
rated, we screwed the bolt of the  ptO2 probe (LICOX, 
Integra LifeSciences, Plainsboro, NJ) superficially into 
the skull in the approximate angle necessary to reach 
the area of interest. We then performed an immedi-
ate bolt CT scan to verify the trajectory of the bolt. In 
order to reduce the radiation dose, the scan covered 
only the supraorbital part of the skull including the bolt 
end down to roof of the third ventricle. The CT data 
set was immediately reconstructed along the trajectory 
of the bolt. If necessary, we adjusted the trajectory by 
adapting the angulation of the bolt. In this case, a sec-
ond bolt CT was performed to confirm the correct tra-
jectory. This procedure was repeated until the correct 
bolt angulation was found. Then, the surgeon screwed 
the bolt firmly into the skull and inserted the sheath of 
the  ptO2 probe. Another CT scan was acquired to con-
firm the correct location of the sheath. After insertion 
of the  ptO2 probe, a final postoperative CT scan was 
performed to assess the correct location of the tip of 
the  ptO2 probe in the area of interest.
If duration of  ptO2 monitoring exceeded one week, 
we routinely exchanged probes.
Our threshold for the initiation of diagnostic or ther-
apeutic measures is a  ptO2 measurement ≤ 15  mmHg 
for ≥ 10 min. In cases with an evident reason for  ptO2 
decline, e.g., documented vasospasms after SAH, no 
further diagnostic studies were initiated, but thera-
peutic measures were taken directly. These consisted 
of medical measures first (e.g., adjustment of mean 
arterial pressure in case of vasospasm related misery 
perfusion or medical therapy for increased ICP) and 
in refractory cases, interventional measures such as 
local spasmolysis or angioplasty, or surgical interven-
tions (e.g., hemicraniectomy). A detailed description of 
the therapeutic algorithm is given in Fig.  1. The algo-
rithm is consistent with the BONANZA algorithm and 
in large parts with the BOOST-II algorithm, although 
inspiratory oxygen fraction was not increased to cor-
rect  ptO2 values [16].
Data Analysis
The primary endpoint was the successful CT-guided 
positioning of the  ptO2 probe inside the area of inter-
est in the study group. The correct location was evalu-
ated by two raters (L. H. and M. D. R.). Based on the 
target area specified in the operation report, as well 
as the consideration of clinical and imaging character-
istics of each individual patient, each rater retrospec-
tively placed a sphere with a radius of 1 cm (volume of 
4.2  ml) with the point of major interest in the center 
onto the preinterventional CT scan. Overlap with 
preexisting infarcts, hematomas, and contusions was 
avoided. These spheres represented the target location. 
We fused the pre- and postinterventional images then 
and evaluated the location of the probe with respect to 
the sphere. If the tip of the probe was inside the sphere, 
we considered the placement correct. Conversely, if the 
tip of the probe was located outside the sphere, we con-
sidered the placement incorrect. If both raters agreed 
on the correct placement of the probe, the primary 
endpoint was reached and the positioning successful. 
If one of the raters considered the tip inside the target 
location, while the other rater did not, or if both raters 
agreed on the incorrect placement, we considered the 
placement unsuccessful and the primary endpoint was 
not reached. For image manipulation and fusion, the 
software Elements (Brainlab, Munich, Germany) was 
used.
Secondary endpoints included radiological and clinical 
parameters. We evaluated for the study and the historical 
control group complications from probe insertion, clini-
cal consequences from  ptO2 measurements, as well as 
clinical outcome according to the modified Rankin Scale 
(mRS) after 6 months. A good outcome was considered a 
mRS score of ≤ 3.
Radiological outcome was assessed by a board-certi-
fied, senior neuroradiologist (F. W.) and included com-
plications from probe insertion, determination of the 
vascular territory of the probe, and assessment of vasos-
pasm, hypoperfusion, or ischemia over the course of  ptO2 
monitoring until 7  days thereafter inside or outside the 
target area of the probe. Furthermore, we recorded the 
appearance of any new parenchymal lesions or ischemia 
on the latest imaging study available from each patient.
Fig. 1 Therapeutic algorithm in case of decline of  ptO2 measurements. CPP cerebral perfusion pressure; CSF cerebrospinal fluid; MAP mean arterial 
pressure; PTA percutaneous transluminal angioplasty; SAH subarachnoid hemorrhage; TBI traumatic brain injury
Clinical data and  ptO2 values were extracted from the 
institutional electronic Patient Data Management System 
(Centricity™ Critical Care, General Electric Company, 
GE Healthcare, USA). The system automatically docu-
ments all  ptO2 and ICP values, hemodynamic, and res-
piratory variables in intervals of 2  min. Further clinical 
data such as GCS score, fluid balances, and administered 
drugs are entered manually by the bedside team.
Additionally, for the study group only, the total number 
of CT scans for probe insertion as well as the cumulative 
radiation exposure was documented for each patient. The 
cumulative radiation dose was calculated as the sum of 
the dose-length product (DLP) of each CT scan:
where CTDI = computed tomography dose index and 
nT = product of the number of slices and slice thickness. 
To calculate the effective dose (E), a conversion factor of 
0.0021 was applied:[31]
The duration of the intervention was derivated from the 
acquisition time of imaging data. The total duration was 
defined as the time interval between the last diagnostic 
scan, i.e., before insertion of the bolt, and the final con-
firmatory scan. Thus, the total duration includes the time 
for diagnostic imaging analysis, target selection, entry 
point calculation, bolt insertion, analysis and correction 
of the trajectory, any additional scans, and insertion of 
the probe. The extra duration of using CT-guidance was 
defined as the time interval between the first scan with 
the bolt in situ and the final confirmatory scan. The extra 
duration represents the time for the analysis and correc-
tion of the trajectory, any additional scans, and insertion 
of the probe.
Based on the three vascular territories available (ACA, 
watershed zone, and anterior MCA), we grouped the cor-
rectly placed probes together and measured the location 
of the cranial entry points and trajectories of the  ptO2 
probes. The location of the entry point as distance from 
the midline in the coronal plane and as distance from the 
coronal suture in the sagittal plane was measured. Fur-
thermore, the probe trajectory was assessed in degrees 
angulation in a sagittal projection with reference to the 
Frankfurt horizontal plane as well as in a coronal projec-
tion with reference to the midline.
Statistics
We will report results of the primary outcome descrip-
tively. In case a patient had bilateral probes placed, we 
evaluated both sides independently.
For comparison of entry sites and trajectories between 
groups of different vascular territories, a Kruskal–Wallis 
DLP = CTDIVolx nT,
E = DLP x 0.0021.
test was applied. Continuous variables are reported as 
mean and standard deviation. We compared the study 
group and the control group using a Mann–Whitney U 
test for continuous variables and Chi-Square or Fisher’s 
exact test for nominal variables. Statistical analysis was 
performed using the statistical software SPSS (IBM, Ver-
sion 25).
We addressed missing values first by re-analyzing the 




Twelve patients had a CT-guided  ptO2 probe placed 
between October 2017 and April 2019. One patient had 
to be excluded because of his age < 18 years. Six of them 
had a unilateral probe placed, while the other five under-
went bilateral probe placement. Thus, 16 probes in eleven 
patients were available for analysis in the study group 
(Table 1).
Twenty-one patients had a  ptO2 probe placed in con-
ventional, free-hand technique between January 2010 
and October 2017. From this group, we excluded six 
patients because of withdrawal of care within 24  h of 
probe placement (n = 3), lack of meaningful  ptO2 values 
due to a technical error (n = 1), or missing documenta-
tion (n = 2). In the remaining 15 patients of the control 
group, eleven patients had bilateral and four patients 
unilateral probes placed. Thus, 26 probes were analyzed 
in the control group. Baseline characteristics of study 
and control patients did not differ significantly (Table 2). 
However, there was a trend toward younger age in the 
study group.
Mean duration of  ptO2 monitoring was longer in the 
study population (8.81  days, range 1–13  days) than in 
the control group (4.33 days, range 1–8 days) (p < 0.001). 
Clinical and radiological follow-up data were available 
for all patients of the study group, whereas no radiologi-
cal follow-up was available for three patients with four 
probes of the control group.
Probe Placement in the Study Group
The primary endpoint of successful probe placement was 
met with 15 (93.75%) probes in the study group. Rater 1 
and 2 considered 15 probes being inside the target area, 
while both raters agreed on the misplacement of the 
same probe (right sided probe of patient 3).
Radiologically, two probes were inserted into the 
vascular territory of the ACA, three probes into the 
watershed zone, and 11 probes into the anterior part 
of the vascular territory of the MCA. Perfusion imag-
ing at time of probe insertion revealed hypoperfusion 
in the territory of ten probes. For five probes, perfusion 
imaging showed normal perfusion and for one probe, 
no perfusion imaging was available at insertion. Of 
note, no patient showed hypoperfusion exquisitely out-
side the vascular territory of the probe.
We placed ten probes under guidance of our CT 
scanner (128-slice CT scanner, Somatom Definition 
Edge, Siemens Healthcare, Erlangen, Germany) and 
six probes in the angiography suite with guidance of a 
Flat-Panel Detector Computed Tomography (FD-CT, 
DYNA-CT; Siemens “Artis” Models, Siemens Health-
care, Erlangen, Germany).
The location of the cranial entry points and the tra-
jectories of the  ptO2 probes for different vascular ter-
ritories are given in Table 3. Individual entry points and 
trajectories are displayed in Figs. 2 and 3. Of note, the 
choice of an entry point was limited due to an exist-
ing external ventricular drain on the same side in 8/16 
(50%) of the probes placed. While comparison of entry 
points showed no significant differences for different 
vascular territories (p = 0.934 for distance to midline, 
p = 0.922 for distance to coronal suture), a nonsignifi-
cant trend for different angulations was found in the 
sagittal projection (p = 0.107).
The average number of CT scans performed for probe 
placement per patient was 3.91 (± 2.07). The mean DLP 
and effective dose were 1595.17 (± 769.00) mGycm and 
3.34 (± 1.61) mSv, respectively, per patient.
We repositioned the bolt in order to adjust the tra-
jectory before insertion of the probe sheath with the 
stylet on average 0.8 times (range 0–4). The average 
total duration of probe placement was 40  min 40  sec 
(± 20 min 43 sec). The average extra duration for CT-
























































































































































































































































































































































































































































































































































































































































































































Table 2 Comparison of  baseline characteristics 
between  study group (CT-guided placement) and  control 
group (conventional placement)
Mean values with standard deviation are given for continuous variables







Age (years) 46.87 (± 14.09) 57.61 (± 13.90) 0.077
Female sex 8 (72.7%) 9 (60.0%) 0.683
Bilateral placement 5 (45.5%) 11 (73.3%) 0.228
Disease 0.628
TBI 2 (18.2%) 2 (13.3%)
SAH 7 (63.6%) 12 (80%)
ICH 1 (9.1%) 1 (6.7%)
other 1 (9.1%) 0
Therapeutic Implications of  ptO2 Measurement
In the study group, declining  ptO2 measurements trig-
gered 68 diagnostic or therapeutic interventions as a 
direct consequence of  ptO2 monitoring. With a total 
duration of 141 days of measurement, this results in a 
rate of 0.48 interventions per probe per day of meas-
urement. Considering a mean duration of 8.81  days 
of monitoring per probe, a unilateral  ptO2 probe trig-
gered on average 4.23 diagnostic or therapeutic adjust-
ments per patient. Out of 68 diagnostic or therapeutic 
interventions, 9 consisted of diagnostic cranial imaging, 
while 59 interventions were therapeutic adjustments. 
Thirty-six were noninvasive therapeutic adjustments 
(0.25 per probe per day). The majority of them included 
increasing mean arterial pressure to optimize cerebral 
perfusion, optimizing respiratory parameters, increas-
ing sedation, or medical therapy to decrease ICP. 
Additionally,  ptO2 measurements initiated 23 invasive 
therapeutic interventions (0.16 per probe per day). All 
of them consisted of angiographic interventions (spas-
molysis or angioplasties).
Table 3 Insertion site and trajectory of  ptO2 probes according to vascular territory
Location of the cranial entry point and trajectory of the  ptO2 probes for different vascular territories. Mean± standard deviation is given for all values. The location of 
the entry points is given as distance from the midline in a coronal plane as well as distance from the coronal suture in the sagittal plane. The trajectories are given in 
degrees angulation in a sagittal projection with reference to the Frankfurt horizontal plane as well as in a coronal projection with reference to the midline
ACA Anterior cerebral artery territory, Watershed Watershed zone between the anterior and middle cerebral artery territory, MCA Anterior portion of the middle 
cerebral artery territory, cm Centimeter.* Kruskal–Wallis test
ACA Watershed MCA p value*
Midline (cm) 3.79 (± 0.92) 3.55 (± 1.73) 4.05 (± 0.72) 0.934
Coronal suture (cm) 1.93 (± 0.60) 2.24 (± 1.30) 1.90 (± 1.03) 0.922
Sagittal (degrees) 86.70 (± 13.44) 55.87 (± 22.24) 42.89 (± 19.39) 0.107
Coronal (degrees) 41.70 (± 8.49) 22.23 (± 21.00) 28.15 (± 13.37) 0.392
Fig. 2 Individual entry points of all successfully placed probes with relation to the midline (horizontal line) and coronal suture (vertical line). All 
entry points are projected on the same side of the skull for simplification. Entry points of probes in the ACA territory are depicted green, while those 
of probes in the watershed zone are blue and the anterior MCA territory red. While most entry points cluster 3.5–4 cm lateral to the midline and 
2 cm anterior to the coronal suture (to the left in the image), the different groups of vascular territories did not diverge significantly. The larger, black 
dot marks Kocher’s point as an illustrative reference
In comparison, the average rate of diagnostic and 
therapeutic interventions per probe per day triggered 
by declining  ptO2 measurements was significantly less 
frequent in the control group (0.15 diagnostic or thera-
peutic interventions per probe per day of measurement, 
p = 0.007). The rate of noninvasive and invasive therapeu-
tic adjustments per probe per day was also significantly 
less frequent in the control group (0.07 and 0.04, respec-
tively; p = 0.002 and 0.011, respectively). Considering 
a mean duration of 4.33 days of measurement, a unilat-
eral probe triggered in the control group on average 0.65 
diagnostic or therapeutic adjustments.
Clinical and Radiological Outcome
The mean duration of radiological follow-up in the study 
group was 5.58 months (range 1–14). MRI was available 
in five and a CT scan in six patients. Radiological long-
term follow-up showed no ischemic infarcts in eight 
hemispheres with a probe. A proximal infarct, inside 
the vascular supply territory captured by the probe, was 
found in one hemisphere. Distal infarcts, outside the vas-
cular territory captured by the respective probe, were 
present in six hemispheres. The most frequent location 
of an infarct outside the area captured by the probe was 
the central MCA territory with a probe placed in the 
anterior MCA territory or the watershed zone (Fig.  4). 
In the patient with an infarct inside the vascular territory 
of the probe, the anterior MCA territory was affected. 
The lesion in the territory of the probe resembles a small 
lacunar ischemia (Fig. 5). In that patient, eight therapeu-
tic adjustments were made based on the  ptO2 measure-
ment in the respective hemisphere. Out of four patients, 
who had no diagnostic or therapeutic measures initiated 
based on the  ptO2 measurements, three had no ischemic 
infarcts at all on the last follow-up imaging, while one 
had an ischemic infarct outside the vascular territory of 
the probe.
At 6  months, 8 patients (72.73%) of the study group 
showed a good outcome (mRS ≤ 3), whereas 3 patients 
showed a mRS of 4. Of note, 6 patients reached an excel-
lent outcome with a mRS of 0 or 1. Comparing the dis-
tribution of mRS scores yielded a significantly better 
outcome in the study group compared to the control 
group (p = 0.024). While 72.73% of patients in the study 
group reached a good outcome, only 46.67% in the con-
trol group did so (p = 0.246). Mortality in the study group 
was significantly lower than in the control group (0% vs. 
40%; p = 0.024).
Complications
None of the patients of the study group suffered from a 
direct complication of probe placement. While a small 
epi- or subdural hematoma was visible on the postopera-
tive CT scan in five probes, none of them was clinically 
Fig. 3 Individual trajectories of all successfully placed probes with relation to the axial plane parallel to the Frankfurt horizontal plane (left) and the 
sagittal plane in the midline (right). All trajectories are projected on the same side of the skull for simplification. Trajectories of probes in the ACA ter-
ritory are depicted green, while those of probes in the watershed zone are blue and the anterior MCA territory red. As a rule of thumb, the insertion 
into the anterior MCA territory was angulated aiming at the nasion in the coronal and the inion in the sagittal plane. Contrary, the insertion into the 
ACA territory was angulated at the contralateral superior temporal line in the coronal plane and the zygomatic protuberance in the sagittal plane. 
For the watershed zone, an angulation aiming at the nasion in the coronal plane and the tragus in the sagittal plane serves as a rough estimate
relevant or required any intervention. Median diam-
eter of the hematoma measured on coronal images was 
4.0 mm (range 2.9–6.2 mm). In one patient, a new intrac-
erebral hematoma was visible on follow-up scans, which 
was most likely related to the removal of the probe. The 
patient remained asymptomatic for this bleeding. One 
patient of the study group and two patients in the con-
trol group developed ventriculitis, which were probably 
related to concomitant placement of an external ventric-
ular drain. No other infectious complications occurred.
Discussion
Probe Placement
Our results demonstrate the feasibility of accurate, indi-
vidualized placement of  ptO2 probes by CT-guidance. 
By using this easy technique, we placed the probes in 
the area of interest with a success rate of 93.75%. Probe 
misplacement occurred due to procedural errors and 
anatomical difficulties. Procedural errors comprise fail-
ure to align the imaging reconstruction of the trajectory 
perfectly with the bolt and incorrect measurement of the 
distance along the trajectory. Furthermore, insertion in a 
flat angle in relation to the skull can be difficult, because 
drilling in a flat angle is technically more challenging and 
the insertion of the bolt through a longer bony tunnel 
restricts the number and extent of possible corrections of 
the trajectory. In our study, we did not perform further 
correctional maneuvers once the probe was inserted.
Furthermore, our analysis highlights the importance of 
the trajectory chosen rather than the entry point in order 
to reach a specific vascular territory. Probes were usu-
ally inserted 3.5–4 cm lateral to the midline and approxi-
mately 2 cm in front of the coronal suture. In case of an 
existing external ventricular drain with the entry site at 
the Kocher’s point, the insertion site of the  ptO2 probe 
can be estimated 1–2 cm further anterior and lateral to 
the existing drain. This distance should not be less than 
Fig. 4 Infarction outside the vascular territory of the probe in patient 4. The patient suffered from aneurysmal subarachnoid hemorrhage with 
subsequent severe vasospasms causing an ischemic infarction. While the probe was inserted into the anterior MCA territory (left, brain CT without 
contrast), an ischemic infarction developed in the central MCA territory and was visible on initial MR scan (middle, diffusion-weighted imaging) and 
on follow-up MR imaging (right, T2-weighted image)
Fig. 5 The only ischemic lesion inside the vascular territory of the 
probe occurred in the left frontal lobe of patient 1 (T2-weighted 
image of brain MR scan). The patient suffered from aneurysmal 
subarachnoid hemorrhage with subsequent severe vasospasm. The 
lesion resembles a small demarcated lacunar infarct (arrow). The most 
likely cause of ischemia in this patient was either vasospasm or an 
embolic lesion secondary to an angiographic intervention. However, 
it remains unclear, whether it was related to the introduction of the 
probe itself or represents a true ischemic lesion
1  cm–avoid conflicts with the bolt of the external ven-
tricular drain.
As a rule of thumb, the insertion into the anterior MCA 
territory needs an angulation aiming at the nasion in the 
coronal and the inion in the sagittal plane. The insertion 
into the ACA territory warrants a steep trajectory aiming 
at the zygomatic protuberance in the sagittal plane and 
at the contralateral eyeball in the coronal plane. For the 
watershed zone, an angulation aiming at the nasion in the 
coronal plane and the tragus in the sagittal plane serves 
as a rough estimate. Obviously, the angulation to the cor-
onal plane should be increased the more lateral the entry 
point is chosen.
The total duration for  ptO2 probe placement includ-
ing the time for diagnostic imaging analysis, target selec-
tion, entry point calculation, bolt insertion, analysis and 
correction of the trajectory, any additional scans, and 
insertion of the probe was 40  min 40  sec. This burdens 
institutional resources, since the CT scanner is occupied 
for this duration. However, the extra duration of CT-
guided placement compared to conventional free-hand 
placement was only 15 min 28 s. In our study, no patient 
was transferred to the CT scanner or angio-suite solely 
for the purpose of probe placement. Rather, in case of 
neurological deterioration indicating the need for  ptO2 
probe placement, cranial imaging was performed anyway 
to rule out surgical lesions or ischemia.
Clinical Implications and Outcome
Since  ptO2 probes provide focal measurements reflect-
ing oxygen tension within a small volume of brain near 
the sensor, the spatial relationship of the probe to the site 
of injury is critical when interpreting measurements [1]. 
Several experimental and clinical studies demonstrated 
lower  ptO2 values in perilesional or abnormal brain com-
pared to healthy brain tissue, highlighting the interaction 
between  ptO2 values and the probe position [29, 32–34]. 
In a study of 405 patients, Ponce et  al. demonstrated a 
stronger relationship of outcome to  ptO2 values in abnor-
mal brain compared to  ptO2 values in normal-appearing 
brain [33]. Similarly, Lindner et  al. also found a signifi-
cant association between brain tissue hypoxia and poor 
functional outcome with  ptO2 probes placed into per-
ilesional brain tissue, whereas measurements in healthy 
tissue showed no association to outcome [34]. Kofler 
et al. showed that assessment of cerebral metabolism in 
the immediate vicinity of a brain lesion has prognostic 
impact [28]. However, placement of a probe into a paren-
chymal contusion is futile, since the  ptO2 values of this 
irreversibly damaged tissue cannot be influenced by ther-
apy [35]. Therefore, the  ptO2 probe should be placed in 
potentially endangered, but salvageable perilesional brain 
tissue at least 1 cm away from already unviable tissue [21, 
22, 28, 36]. This parallels the concept of the penumbra in 
ischemic stroke treatment [37].
If placed in a routine, free-hand fashion, less than half 
of the probes reside in perilesional tissue, while up to 
17% will be within a lesion [38]. Intraoperative, framel-
ess stereotaxy can be used to place a probe into a desired 
area of interest [39–41]. Unfortunately, this approach can 
only be applied in the operating room and depends on 
the availability of image-guidance by a 3D neuronaviga-
tion system. The use of CT-guidance is advantageous for 
several reasons: (1) Since the selection of a specific target 
necessitates cranial imaging to visualize the pathology 
and CT is used in most instances, no additional trans-
ports are necessary, (2) a postinsertional CT scan is rec-
ommended in all cases and facilitated without further 
transportation and (3) the technique is easy to use, safe 
and allows for correctional maneuvers before the probe is 
inserted into the brain parenchyma.
Our technique allowed us to insert  ptO2 probes specifi-
cally into areas of critical perfusion, which are at risk for 
tissue hypoxia. Decreasing  ptO2 measurements in these 
endangered areas lead to 59 therapeutic interventions. 
Thereby, prevention of ischemic tissue damage in the area 
of the probe was possible in all except one case. Impor-
tantly, eight therapeutic adjustments were made in that 
patient based on the  ptO2 measurements, reflecting the 
attempt to prevent infarction with aggressive treatment. 
Thus, ischemic infarct was probably due to unsuccess-
ful treatment rather than failure of  ptO2 measurement. 
Furthermore, we were able to limit ischemic damage to 
vascular territories outside the area of the probe. This 
underscores the importance of correct placement of a 
probe into the most critically perfused area with the 
highest risk for ischemia.
Specific monitoring of areas at risk and aggressive 
treatment probably had a positive effect on outcome: 
eight patients (72.73%) reached an excellent outcome 
with a mRS 1 or 2, while only three patients (27.72%) had 
an unfavorable outcome with a mRS of 4. Formal com-
parison to other studies is difficult because of the het-
erogeneity of our cohort. All patients with TBI reached 
a good outcome, despite a maximal initial GCS of 8. In 
a recent, large prospective trial of patients with severe 
TBI and a GCS ≤ 8 only 50% reached a favorable outcome 
[42]. Five of seven patients (71.43%) suffering from SAH 
reached a good outcome in our cohort. Traditionally, 
vasospasm reduces the frequency of good outcome after 
SAH from 70 to 44% and increases mortality from 17 to 
31% [43]. Our results also compare favorably with the 
prospective cohort of the recent HIMALAIA-trial, where 
48.78% of patients had a poor outcome [44]. However, 
the outcome of our study group has to be interpreted 
cautiously, because the cohort is a mix of SAH, TBI, ICH, 
and other pathologies with a small sample size in a retro-
spective, single institution setting.
Comparison of the study group to a historical con-
trol group with conventionally placed  ptO2 probes from 
our institution supports the finding that specific place-
ment of a  ptO2 probe in an area at risk has the potential 
to improve the value of  ptO2 monitoring and ultimately 
outcome. This is reflected by a significantly higher rate of 
diagnostic and therapeutic interventions per probe per 
day in the study group compared to the control group. 
This, in turn, might have contributed to a significantly 
better outcome at six months in the study group.
Radiation Exposure
The radiation exposure with an average number of scans 
of 3.91 per patient represents the disadvantage of our 
method. In order to reduce the radiation exposure, the 
scans were routinely limited to the supraorbital cranium. 
Thereby, the mean DLP was reduced to 1595.17 mGycm. 
Importantly, this includes a scan after the procedure in 
order to confirm the location of the probe and exclude 
hemorrhage in the vicinity of the probe, whereby the 
measurement would be jeopardized. A confirmatory 
scan is recommended in clinical practice as well as in 
ongoing trials (BONANZA), and imposes a radiation 
exposure of 600–700 mGycm by itself if performed as a 
regular CT scan [1, 45]. Of note, as an alternative to  ptO2 
measurements in the diagnosis of vasospasms, angio-
CT combined with perfusion-CT imaging is often used 
and imposes a radiation exposure of 3000–3400 mGycm 
[46–48].
We acknowledge the need for reducing radiation expo-
sure when CT-guided probe insertion is used clinically. 
In our practice, a first scan was performed after place-
ment of the bolt, another after introduction of the probe 
sheath with the stylet, and another after the insertion of 
the probe itself. With more experience in the CT-guided 
technique, the scan after insertion of the probe sheath 
with the stylet can be omitted. This has the potential to 
reduce the radiation exposure by almost a quarter and 
will be employed in the future.
Although radiation exposure is a concern, the potential 
benefit of a better outcome through improved monitor-
ing and aggressive treatment in this patient population 
with a critical prognosis likely offsets the harm by the 
radiation exposure.
Limitations
Several limitations apply to our analysis. Our results 
were obtained by a retrospective analysis. Furthermore, 
this was a single-center study with a limited number of 
patients that lacks external validation. Directly comparing 
patient groups is of limited value due to the heterogene-
ity of the patient population including different severi-
ties and various pathologies. However, the heterogeneity 
of our cohort is also one of the strengths of our study, 
because the consistency of our results across various 
pathologies renders the results more generalizable.
We selected a historical control group with convention-
ally placed probes from our institution. Interpretation of 
the results of the comparison to our study group war-
rants caution for several reasons: (1) although the differ-
ence did not reach statistical significance, the study group 
was considerably younger than the control group, which 
in turn impacts outcome. (2) The higher rate of interven-
tions in the study group could simply reflect an overall 
more aggressive treatment approach, irrespective of the 
placement of a  ptO2 probe. (3) Duration of measurement 
of  ptO2 was significantly longer in the study group, which 
might also reflect an overall more aggressive treatment 
approach. However, this could also originate from the 
clinician’s impression of less valuable monitoring data 
in the control group, which might have shortened the 
duration the probe was left in situ. (4) Since ptO2 probes 
were routinely placed by CT-guidance after October 
2017 and in conventional technique before, the differ-
ence in treatment intensity and outcome might originate 
in an improvement in neurocritical care over time, since 
two separate time periods are compared. (5) Finally, the 
retrospective nature and small sample size of our study 
and control group impose the potential for selection, per-
formance, and other biases. In order to reduce potential 
biases, we excluded patients who had care withdrawn 
within 24 h from the control group.
Conclusions
Since  ptO2 probe measurements only represent small 
brain volumes, concise probe placement is critical. CT-
guidance is an accurate and easy technique for place-
ment of a  ptO2 probe in a particular area of interest in 
patients with critical cerebral oxygen supply. By applying 
our technique of individualized  ptO2 probe placement, 
the value of monitoring probably can be improved, which 
has the potential to translate into better patient outcome.
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